UroGen Pharma (URGN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.03
- Estimate
- $0.10
- Surprise
- -131.0%
- Revenue (period 2026-09-30)
- $89.0M
- Score today
- 6.2/10
Revenue source: xbrl.
How the report landed
UroGen Pharma (URGN) reported a wider loss than forecast — adjusted EPS of -$0.03 against the $0.10 estimate (a 131.0% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates URGN Hold at 6.2/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -131.0% surprise compares with a -34.4% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Earnings estimates trending UP
What argues against it
- Concentration risk — Product: Jelmyto and Zusduri
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7)
- Consecutive earnings misses (3)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $28.74
- Price target
- $53.69
- Stop
- $26.73
- Upside to target
- +86.8%
- Reward-to-risk
- 6.3:1
Risk check: RSI 22 — a level conventionally read as oversold; trading volume is running 2.2× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
URGN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.40B
- P/E (fwd)
- 10.4
- 52-week range
- $16.50–$50.81
- Off 52-week high
- 43.4%
- RSI (14)
- 22
- Volume vs avg
- 2.21×
- Score today
- 6.2/10